Belzutifan is a special kind of medicine that blocks HIF-2α, a protein linked to VHL-related RCC, also known as clear cell renal cell carcinoma. It helps cut down on the low-oxygen signal in tumors. You can get this medicine in 40 mg tablets.
They usually suggest you take 120 mg each day. The medicine comes in bottles that hold 90 tablets. It’s designed to tackle the VHL mutation in RCC.
By blocking HIF-2α, it brings back the right amount of oxygen to tumor cells and helps stop them from growing because they’re starved of oxygen.
